Introduction
Aurora-A is one of three serine/threonine kinases (A, B and C) that are evolutionally conserved and regulate mitotic progression in various organisms (reviewed in Katayama et al., 2003; Crane et al., 2004; Ducat and Zheng, 2004; Meraldi et al., 2004) . Aurora-A is localized at the centrosome during interphase, translocated to the mitotic spindle in early mitotic phase and degraded after metaphase transition. It has been demonstrated that activation of Aurora-A is required for mitotic entry, centrosome maturation and separation and G2 to M transition (Marumoto et al., 2002; Meraldi et al., 2002; Anand et al., 2003; Hirota et al., 2003; Giet et al., 2005) . Overexpression of Aurora-A also results in defective spindle assembly checkpoint, allowing cells with abnormal chromosomal separation to enter anaphase, leading to aneuploidy (Zhou et al., 1998; Stenoien et al., 2003) .
Human Aurora-A gene is located at chromosome position 20q13, a site that is frequently amplified in breast, bladder and colorectoal cancers (Zhou et al., 1998; Sen et al., 2002; Aust et al., 2004) . Aurora-A is frequently overexpressed in various cancers, including breast, colorectal, pancreatic, ovarian, esophagel, gastric and bladder cancers (Bischoff et al., 1998; Zhou et al., 1998; Tanaka et al., 1999 Tanaka et al., , 2005 Kamada et al., 2004; Giet et al., 2005; Hu et al., 2005) . It was demonstrated that overexpression of Aurora-A was sufficient to transform NIH3T3 and immortalized Rat-1 cells and that the transformed cells could form tumors when implanted in nude mice (Bischoff et al., 1998; Zhou et al., 1998) . These studies provide compelling evidence that Aurora-A acts as an oncogene. Further studies revealed that the transforming ability of Aurora-A might be correlated with phosphorylation of p53 at serine 215 (S215) and S315. The phosphorylation of these sites is responsible for the inactivation of p53 transactivation activity and degradation of p53, respectively Liu et al., 2004) . It was recently shown that Aurora-A physically binds and phosphorylates BRCA1 at S308 (Ouchi et al., 2004) . This phosphorylation is correlated with progression of cells from the G2 phase to the M phase, while BRCA1-S308N, a form that cannot be phosphorylated by Aurora-A, behaves like wild-type BRCA1 in reducing number of cells in the M phase when expressed in BRCA1-deficient mouse embryo fibroblasts (MEFs). As BRCA1 deficiency impairs G2/M cell cycle checkpoint (Xu et al., 1999 (Xu et al., , 2001 , it is conceivable that G2 to M transition caused by Aurora-A overexpression is, at least in part, mediated by reduced function of BRCA1.
However, a recent study revealed a more complex relationship between Aurora-A and tumorigenesis. Overexpression of Aurora-A failed to induce oncogenic transformation in primary MEFs (Anand et al., 2003) . Indeed, the lack of colony formation was also observed when Aurora-A was overexpressed together with a trans-dominant p53 that eliminates the p53-mediated DNA damage checkpoint or together with expression of BCL-2 that eliminates an apoptotic pathway. It was also shown that conditional expression of Aurora-A in the mammary epithelium by a Cre-LoxP approach induced abnormalities in the G2 checkpoint and the spindle checkpoint and the cytokinesis, leading to chromosome instability. However, the transgenic mice failed to develop mammary tumors (Zhang et al., 2004) . These observations suggest that overexpression of Aurora-A alone is not sufficient enough for inducing tumor formation in vitro and in vivo, and additional factors may be required for Aurora-A-mediated tumorigenesis.
In this study, we investigated whether Aurora-A could act as an oncogene in mice by directly expressing it in the mammary epithelium using the mouse mammary tumor virus (MMTV) enhancer and promoter. Our study indicated that overexpression of Aurora-A could cause mammary tumor formation and tumor incidence increases with the inactivation of p53. Importantly, we showed that expression of Aurora-Ainduced genetic instability at stages precede mammary tumor formation. This event is associated with activation of the AKT pathway that may serve as surviving signals for the Aurora-A-overexpressing cells.
Results

Generation of MMTV-Aurora-A transgenic mice and analysis of transgene expression
To study a role of Aurora-A in mammary gland development and neoplasia, we generated transgenic mice expressing a human Aurora-A cDNA under transcriptional control of the MMTV long terminal repeat promoter/enhancer (Figure 1a) . Two independently established transgenic lines showed consistently higher levels of Aurora-A expression (Figure 1b) , and were selected for further analysis.
We first examined expression of the transgene in seven organs isolated from both transgenic founder lines using reverse transcriptase-polymerase chain reaction (RT-PCR). Our data indicated that the transgene was expressed in all these organs at varying levels. It was expressed at the highest level in both the mammary gland and salivary gland, followed by kidney, spleen, liver, brain and uterus in a decreasing order ( Figure 1c) . Next, we studied transgene expression during mammary cycle of development by Western blot analysis using an antibody against human Aurora-A. We found that mammary glands of MMTV-Aurora-A mice taken from virgin, 6 days of pregnancy, 4 days after onset of involution, parous and tumor tissue showed gradually increased levels of Aurora-A (Figure 1d ). Our analysis indicated that animals from both transgenic lines showed similar expression pattern and similar phenotypes as will be described below.
Overexpression of Aurora-A results in enhanced mammary branch morphogenesis and cell proliferation To study the potential effect of overexpression of Aurora-A on mammary development and neoplasia, we studied mammary glands of MMTV-Aurora-A transgenic mice. Using whole-mount staining, we examined mammary glands isolated from 2-month-old MMTV-Aurora-A transgenic and wild-type control mice at varying phases during the mammary cycle of development, including virgin, pregnant, lactation and involution. These analyses revealed no significant changes between the transgenic and control glands (data now shown), suggesting that expression of Aurora-A did not interfere with epithelial cell proliferation and differentiation at this stage of time. However, our data indicated that, starting from 4 months of age, the size of the mammary gland of MMTV-Aurora-A mice ( Figure  2b and d) was obviously larger than that of wild-type mice (Figure 2a and c) . We next performed histological analysis of mammary glands. Our data revealed that Aurora-A induces mammary tumor formation X Wang et al although the mammary epithelium of 2-month-old mutant mice was morphologically normal, some areas of epithelium exhibited multiple layers of cells (Figure 2f ) in contrast to only one or two layers of cells in control mice (Figure 2e ). This type of lesion was more frequently observed in the mammary gland of older Aurora-A transgenic mice (not shown).
Our further analysis revealed that majority of mammary glands isolated from older parous MMTVAurora-A transgenic mice (Figure 3b and e) displayed significantly more extensive ductal branching and alveolization compared to mammary glands isolated from age-matched wild-type mice (Figure 3a and d) . It was previously shown that overexpression of Aurora-A activates p53, which may have a significant effect on transgenic phenotypes (Zhang et al., 2004) , we therefore crossed the MMTV-Aruora-A transgenic mice into a p53 heterozygous (p53 þ /À ) mutation background. We showed that the MMTV-Aruora-A;p53 þ /À mice exhibited more extensive branch morphogenesis in their mammary glands than MMTV-Aruora-A transgenic mice (Figure 3c and f). Histological sectioning of mammary glands from control, MMTV-Aruora-A and MMTV-Aruora-A;p53 þ /À mice confirmed this observation (Figure 3g-i) .
To determine the causes for the increased mammary branch morphogenesis and hyperplasia in the MMTVAurora-A mice, we analysed cell proliferation and apoptosis in mammary epithelial cells of transgenic and control mice. Our analysis on sections of mammary glands of 4-month-old parous mice revealed significantly more 5-bromo-2-deoxyuridine (BrdU)-positive cells in MMTV-Aurora-A mammary epithelium than control epithelium (Figure 3j and k). BrdU-positive mammary epithelial cells in MMTV-Aurora-A mice maintained a high level when measured at 12 months of age (Figure 3m ). The BrdU-positive fraction increased further to 36% in MMTV-Aurora-A;p53 þ /À mammary glands (Figure 3l and m). Increased cell proliferation was also confirmed by using a marker for mitotic cells that detects histone H3 phosphorylation (Figure 3n-q) . In contrast, our terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay did not detect any obvious differences in apoptosis in mammary glands with above genotypes at multiple stages analysed (data not shown). Thus, the increased branch morphogenesis and alveolization are primarily caused by increased cell proliferation due to the overexpression of Aurora-A, instead of an alteration in cell death. 
Aurora-A induces mammary tumor formation X Wang et al
Overexpression of Aurora-A results in mammary tumor formation It was shown previously that expression of Aurora-A in mammary epithelium after one cycle of pregnancy results in mammary hyperplasia but not tumor formation (Zhang et al., 2004) . To study potential effects of our MMTV-Aurora-A on mammary neoplasia, we followed cohorts of animals that have been gone through multiple cycles (at least 5) of pregnancy for tumor formation. We found that hyperplastic, noninvasive focal lesions were frequently observed in the mammary glands of MMTV-Aurora-A and MMTVAruora-A;p53 þ /À transgenic mice over 1 year of age (Figure 4a and b).
MMTV-Aurora-A mice started to develop visible mammary tumors at 9 months of age, and the tumor incidence steadily increased as the animals became older ( Aurora-A induces mammary tumor formation X Wang et al spindle cell carcinoma, were also observed ( Figure 4f ). In contrast, a total of 25 multiparous wild-type controls did not display any tumors by 20 months of age ( Figure 4d ). MMTV-Aurora-A transgenic mice also exhibited uterine hyperplasia (n ¼ 3, Figure 4g ), ovary tumor (one) and kidney tumor (one) among 33 mice examined.
Since MMTV-Aurora-A is also expressed in mammary glands of virgin mice with lower levels, we followed 12 virgin MMTV-Aurora-A mice up to 24 þ /À (n ¼ 39) female mice. WT (n ¼ 25) and p53 þ /À (n ¼ 15) mice were used as controls. No tumors were detected in the control mice, however, one wild-type and two p53 þ /À mice died at late stages and were included in the curves. (e and f) An adenocarcinoma (e) and a spindle cell carcinoma (f) developed in the MMTV-Aurora-A mice. (g) An example of uterus hyperplasia (arrow) developed in MMTV-Aurora-A mice. (h) Southern blot analysis of tumor DNA digested by EcoRI and probed by p53 cDNA probe. The first three mammary tumors were developed from MMTV-Aurora-A;p53 þ /À mice. The second and the third lanes have significant weaker intensity of wide-type allele (16 kb). The last lane was a mammary tumor developed from MMTV-Aurora-A;p53 þ / þ mice, which maintained the wild-type p53. (i and j). p53 protein levels revealed by Western blot analysis. The first lane in (i) was mammary gland isolated from a p53 À/À mice. Two of out three tumors isolated from MMTV-Aurora-A;p53 þ /À mice showed significant lower levels of p53. We observed no obvious differences between mammary glands isolated from wild-type and MMTV-Aurora-A mice at a pre-malignant stage (j).
Aurora-A induces mammary tumor formation X Wang et al months of age. We found that only one (8.3%) developed a mammary tumor. This observation indicates that MMTV-Aurora-A mice developed mammary tumors at higher frequency after they were continuously mated perhaps due to exposure of increased levels of estrogen. p53 is a well-known tumor suppressor gene that is mutated in approximately 50% of all human tumors (Morgan and Kastan, 1997) . Aurora kinase A is a key regulatory component of the p53 pathway as overexpression of Aurora kinase degrades p53, leading to downregulation of checkpoint-response pathways and facilitating oncogenic transformation of cells . To assess whether p53 haploinsufficiency could affect tumor formation, we followed tumorigenesis in MMTV-Aurora-A;p53 þ /À mice. Our data indicated that mutant mice started to develop mammary tumors at 6 months of age, and a majority (27/39, 70%) had developed tumors at 18 months of age ( Figure 4d ). In contrast, no mammary tumors were observed in 15 age-matched p53 þ /À female mice, although two died at around 19 months of age of unknown causes. These data demonstrated that the p53 heterozygous mutation significantly accelerated tumor formation in the mammary gland with Aurora-A overexpression.
We next determined a p53 status on tumors developed from MMTV-Aurora-A;p53 þ /À mice. Southern blot analysis revealed loss of heterozygousity in three out of four tumors examined ( Figure 4h , and not shown). The absence or significantly decreased p53 protein levels were confirmed by Western blot analysis (Figure 4i ). This observation provides a molecular basis on the accelerated tumor formation in p53 heterozygous background. Of note, our analysis by Western blot analysis revealed no significant alterations in p53 protein levels between mammary glands isolated from wild-type mice and MMTV-Aurora-A transgenic mice at a pre-malignant stage (Figure 4j ). This observation suggests that the relationship between Aurora-A and p53 is complex, that is although p53 serves as a barrel for Aurora-Aassociated tumorigenesis, the overexpression of Aurora-A does not always result in alterations in p53 protein levels (see Discussion).
Genetic instability occurred prior to tumorigenesis in mammary epithelial cells of MMTV-Aurora-A mice Aurora-A is a centrosome-associated kinase, and plays an essential role in the process of centrosome maturation and separation (Hannak et al., 2001) . To determine whether these abnormalities occur in MMTV-Aurora-A mammary epithelial cells, we studied centrosome in mammary epithelial cells isolated from P16 mammary glands of 4-month-old mice. We found that B10% epithelial cells isolated from MMTV-Aurora-A or MMTV-Aurora-A;p53 þ /À mice contained more than two centrosomes/nucleus as compared to B1% of cells in control glands (Figure 5a, b and e) . This observation indicates that overexpression of Aurora-A resulted in centrosome amplification. It was shown previously in cultured cells that overexpression of Aurora-A resulted in chromosome tetraploidization, which serves as a major route for centrosome amplification (Meraldi et al., 2002) . To investigate this, we performed chromosome spread using mammary epithelial cells. We found that B25% of epithelial cells of MMTV-Aurora-A mammary glands were polyploidy, containing about 80 or more chromosomes, while virtually all cells from control glands were diploid (Figure 5c, d and f) . Of note, about 25% of chromosome spread prepared from mutant cells also showed premature segregation of sister chromatids (Figure 5d and f) . In the tumors, the percentages of both premature chromatid separation and tetraploid cells significantly increased (Figure 5f ), while the percent of cells with abnormal number of centrosome maintained about 10%. As all these abnormalities occurred at premalignant stages long before any physical signs of tumor formation, they may serve as causes rather than consequences of tumorigenesis in MMTV-Aurora-A transgenic mice.
Activation of the AKT pathway in mammary gland and tumors of MMTV-Aurora-A mice Why do cells containing chromosomal abnormalities induced by Aurora-A overexpression not get eliminated? Increased cell survival has been linked to upregulation of activation of oncogenic pathways, especially AKT/ mammalian target of rapamycin (mTOR) pathway (Downward, 1998; Satyamoorthy et al., 2001; Shah et al., 2005) . We therefore determined whether this pathway is activated in mammary glands and tumors of MMTV-Aurora-A mice by immunohistochemical staining.
Our data detected an apparent difference in AKT phosphorylation between wild-type and MMTV-Aurora-A mammary glands at 4 months of age although this was not found at earlier stages (1.5 and 2 months). Phosphorylation of AKT increased dramatically in the pregnant, involuting and parous MMTV-Aurora-A mammary glands compared with controls ( Figure 6a and b, and not shown). Western blot analysis on extracts from mammary glands at different stages of development using an antibody that detects the pAKT confirmed this observation ( Figure 6i ). As mammary glands of both MMTV-Aurora-A and MMTV-Aurora-A;p53 þ /À mice exhibited similar levels of pAKT, we believed that the activation of AKT was not caused by p53 þ /À mutation. Correlated with the higher levels of pAKT, phosphorylated forms of GSK3b and mTOR in MMTV-Aurora-A mammary glands were also significantly increased (Figure 6c-f) . Both mTOR and GSK3b are major downstream targets of Pten/PI3K/AKT signals in eliciting their functions in cell cycle progression, cell growth and proliferation (Mita et al., 2003) . Moreover, it has been shown that high levels of pAKT and pGSK3b are frequently associated with increased nuclear accumulation of cyclin D1 (Diehl et al., 1998; Gotoh et al., 2003) . To investigate this, we next performed immunohistochemical staining using an antibody to cyclin D1. Our data revealed a dramatically Aurora-A induces mammary tumor formation X Wang et al increased accumulation of cyclin D1 in the nucleus of epithelial cells of both premalignant (Figure 6h ) and neoplastic ( Figure 6j ) stages of MMTV-Aurora-A mammary glands. Cyclin D1 plays a major role in promoting cells to enter and complete S phase, the elevated cyclin D1 levels is consistent with fast proliferation of these cells as revealed by dramatically increased BrdU incorporation and histone H3 phosphorylation shown earlier (Figure 3j-q) .
Discussion
Aurora-A is frequently amplified in several human cancers and overexpression of Aurora-A has been detected in 94% of invasive duct adenocarcinomas of the breast (Bischoff et al., 1998; Zhou et al., 1998; Tanaka et al., 1999 Tanaka et al., , 2005 Kamada et al., 2004; Giet et al., 2005; Hu et al., 2005) . However, the causal relationship between overexpression of Aurora-A and tumorigenesis is not fully established due to contradictory data obtained from different experimental systems (Bischoff et al., 1998; Zhou et al., 1998; Anand et al., 2003; Zhang et al., 2004) . Using transgenic mice overexpressing Aurora-A in mammary epithelium, we have made several findings regarding oncogenic ability of Aurora-A and the characteristics associated with tumorigenesis. (1) We showed that overexpression of Aurora-A caused mammary tumor formation at a low frequency after a long latency. (2) The tumor incidence was significantly accelerated by removing one copy of the p53 tumor suppressor gene and most tumors developed in MMTV-Aurora-A;p53 þ /À mice lost the Aurora-A induces mammary tumor formation X Wang et al remaining wild-type allele of the p53, suggesting a role of p53 in repressing Aurora-A-associated tumorigenesis.
(3) Mammary epithelial cells of MMTV-Aurora-A mice displayed severe genetic instability characterized by centrosome amplification, chromosome tetraploidization and premature segregation of sister chromatids. Most notably, these abnormalities occurred at stages before any obvious signs of mammary hyperplasia and tumor formation, suggesting that the tumorigenesis associated with Aurora-A overexpression is secondary to genetic instability. (4) Overexpression of Aurora-A caused activation of AKT pathway, which may protect cells with aneuploid DNA from apoptosis and enable them to continuously proliferate, leading to hyperplasia and tumor formation. These observations shed a light on the mechanism underlying tumorigenesis caused by Aurora-A overexpression. Numerous studies have revealed that Aurora-A plays important functions during normal mitosis (reviewed in Katayama et al., 2003; Crane et al., 2004; Ducat and Zheng, 2004; Meraldi et al., 2004) . Loss of function mutations or RNA interference in genes encoding Aurora-related kinases induce abnormal mitotic phenotypes from yeast to higher eukaryotes (Bischoff and Plowman, 1999; Berdnik and Knoblich, 2002; Giet et al., 2002; Kufer et al., 2003) . On the other hand, overexpression of Aruora-A overrides a number of cell cycle checkpoints leading to mitotic catastrophes (reviewed in Ducat and Zheng, 2004) . The abnormalities include premature entry into M phase, delayed chromosome condensation, cytokinesis failure, centrosome amplification and chromosome polypoid. However, it is not clear which of these events serve as causes for tumorigenesis. Our analysis on the mammary epithelial cells of MMTV-Aurora-A mice revealed that about 10% of cells showed centrosome amplification, and about 25% of cells exhibited chromosome tetraploidization and sister chromatid premature segregation, respectively. These observations provide in vivo evidence that overexpression of Aurora-A results in genetic instability.
Interestingly, we found that the percentages of cells with tetraploid chromosomes and sister chromatids premature segregation further increased in tumor cells while the percentage of cells with abnormal number of centrosome had no changes in tumor cells. This may be accounted for by the following possibilities. First, we suspect that cells with multiple centrosomes may not grow as well as wild-type cells, or they may be killed because they often form multipolar spindle and multinucleation that are not compatible for cell growth in vivo. These situations, alone or in the combination, could prevent the cells with multiple centrosome from accumulation. It is also possible that prolonged effect of Aurora-A overexpression in vivo may induce some changes that repress the ability of Aurora-A in inducing centrosome amplification. An example of such an inhibition effect was reported in both p53 À/À embryonic epithelial cells (Chiba et al., 2000) and fibroblast cells (Oikawa et al., 2005) . p53
À/À cells exhibited centrosome amplification in early passages, however, after 30 passages, the population with abnormal number of centrosome declined and eventually disappeared after passage 50. The inhibition of centrosome amplification is due to the gradually increased expression of BubR1 that restores the normal number of centrosomes in these cells (Oikawa et al., 2005) .
Premature segregation of sister chromatids is often found in cells that are defective in the spindle assembly checkpoint, such as mitotic arrest deficient 2 (Mad2) (Michel et al., 2001) and Brca1 (Wang et al., 2004) mutant cells. The spindle assembly checkpoint plays an essential role in maintaining genome integrity by Aurora-A induces mammary tumor formation X Wang et al holding cells with unaligned chromosomes at metaphase (Amon, 1999; Yoon et al., 2002; Andreassen et al., 2003) . Mad2 selectively binds to unattached kinetochores and is capable of inhibiting anaphase-promoting complex (APC) activity (Sudakin et al., 2001; Tang et al., 2001; Fang, 2002) . It was recently shown that overexpression of Aurora-A abrogates function of Mad2 in inhibiting APC, leading to the failure of the spindle assembly checkpoint (Anand et al., 2003) . Our study provides in vivo evidence for this observation. Thus, the overexpression of Aurora-A in mammary epithelium caused profound genetic instability at premalignant stages that may be responsible for the mammary tumor formation at later stages of life.
We found that phenotypes of MMTV-Aurora-A transgenic mice and the previously reported mice, which carry a mammary-specific disruption of BRCA1, share many similarities, including centrosome amplification, defective spindle assembly checkpoint, and low frequency of tumorigensis after long latency that could be accelerated by a p53 mutation (Xu et al., 1999a, b; Wang et al., 2004) . Interestingly, it was recently shown that Aurora-A physically binds and phosphorylates BRCA1 at S308, and the phosphorylation is correlated with impaired function of BRCA1 in regulating G2/M transition (Ouchi et al., 2004) . Altogether, these findings suggest a link between Aurora-A overexpression and impaired BRCA1 function in genetic instability and tumorigenesis. However, the details regarding interactions between Aurora-A and BRCA1 remain unclear and deserve further investigation.
The spontaneous mammary tumor formation in our MMTV-Aurora-A mice makes it most controversial due to a recent publication by Zhang et al. (2004) , which reported that Aurora-A overexpression in the mammary gland did not induce tumor formation, although it caused mitotic abnormalities and hyperplasia. A number of factors may contribute to the discrepancy between these studies. First, in that study, chicken bactin promoter was linked to the Aurora-A gene through a stopper sequence. The transgene is not expressed unless the stopper is deleted by WAP-Cre, which is activated by pregnancy hormones. As all the mice only went through one full cycle of pregnancy, one possibility is that the deletion of the stopper was incomplete. In our transgenic mice, the Aurora-A is directly linked to the MMTV promoter, which is expressed in the virgin mice at a lower level and pregnant stages at higher levels. To ensure the high levels of transgene expression, we have continuously mated the mice for at least five pregnant cycles to activate and maintain the MMTV promoter activity. Indeed, our data indicated that virgin MMTVAurora-A mice developed mammary tumors at much lower frequency than the mice that had gone through multiple cycles of pregnancy. In addition, the repeated breeding protocol not only activates the MMTV promoter, but also generates high levels of pregnancyrelated hormones that may provide proliferative stimuli for the growth of epithelial cells. Estrogen is a major candidate for the hormones produced during pregnancy given a role of this factor in promoting breast cancer formation (Colditz, 1998; Prall et al., 1998; Gadducci et al., 2005) . Zhang et al. (2004) also reported that overexpression of Aurora-A in mammary epithelium induced an accumulation of p53 and p53-dependent apoptosis. In contrast, it was shown in cultured cells that overexpression of Aurora-A phosphorylates p53, leading to its degradation Liu et al., 2004) . It is therefore proposed that expression of Aurora-A induces tumorigenesis through degradation of p53 Liu et al., 2004) . Differing from these studies, we found that overexpression of Aurora-A in mammary epithelium of our MMTV-Aurora-A transgenice mice did not cause an obvious alteration in p53 protein levels, nor an increase in apoptosis. Why does genetic instability in our MMTV-Aurora-A transgenic mice not activate p53? It is conceivable that expression of Aurora-A in the mammary epithelium of our mutant mice, on one hand, activates p53 through genetic instability, but on the other hand, its continuous expression also induces p53 degradation. As a net result, there is no obvious change in p53. Thus, the relationship between Aurora-A and p53 is complex and different outcomes may occur depending on the extent of genetic instability and sustained levels of Aurora-A expression. The accumulation of p53 in mammary epithelium observed by Zhang et al. (2004) suggests that the expression of Aurora-A activated by one cycle of pregnancy might not reach a high level to degrade p53 efficiently or its expression was high initially but gradually reduced later to a level that failed to inhibit p53.
Most notably, we found that overexpression of Aurora-A results in the activation of AKT and a number of its downstream genes. We have overexpressed Aurora-A in several different types of cultured cells and found it failed to induce AKT phosphorylation, suggesting that the activation of AKT pathway is a long-term effect of Aurora-A overexpression. Consistently, we found that in the MMTV-Aurora-A mice that are younger than 4 months do not show elevated levels of pAKT. Altogether, these observations suggest that genetic instability induced by Aurora-A overexpression may generate profound growth defects that activate a surveillance system, such as p53 to eliminate these cells. On the other hand, the continued Aurora-A expression may also cause p53 degradation and trigger the activation of oncogenes and/or growth factors that protect cells from death, eventually leading to malignant transformation.
It was also recently demonstrated that overexpression of Aurora-A in primary MEF cells did not cause malignant transformation observed in the established cell lines (Anand et al., 2003) . One possibility is that the primary cells do not contain the similar genetic alterations that the established cell lines may have, which support Aurora-A overexpression-induced malignant transformation. The long latency of mammary tumor formation and activation of multiple oncogenes in the mammary epithelium of the MMTV-Aurora-A mice are consistent with this view.
In summary, we have created MMTV-Aurora-A mice and demonstrated in principle that the overexpression of Aurora-A could cause profound genetic instability and mammary tumor formation. We have also demonstrated that the tumorigenesis is associated with activation of a number of oncogenes. This model should be useful for further studying in vivo functions of Aurora-A in regulating cell cycle progression, screening for downstream targets and genetic interaction with other tumor suppressors and oncogenes. In addition, because of the high incidence of Aurora-A overexpression in human breast cancer, the MMTV-Aurora-A mice should be useful for screening agents that inhibit Aurora-A activity in order to develop the therapeutic treatment for breast cancers.
Materials and methods
Cloning and construction of Aurora-A transgenic mice A 1.2 kb fragment of human Aurora-A cDNA was obtained from a human testis cDNA library by PCR using primers Aur-1 (5 0 GGGTCGCAGGTGGGAGCCG 3 0 ) and Aur-3 (5 0 CCCTGGCTCCCTCTGTTAC 3 0 ). This fragment was used to screen the same library to obtain the full-length cDNA for the Aurora-A gene. To generate the Aurora-A expression construct, the MMTV promoter (kindly provided by Dr P Leder) was ligated to the 5 0 of the Aurora-A cDNA followed by insertion of a 800 bp fragment containing a SV40 Poly A sequence to the 3 0 of the cDNA. This plasmid was designated MMTV-Aurora-A.
After digestion of MMTV-Aurora-A with SalI and SpeI, a 5.6 kb DNA fragment was isolated from low-melting gel and DNA was extracted using phenol/chloroform. Linear DNA fragments were dissolved in 10 mM Tris-HCl (pH7.4), 0.1 mM EDTA and microinjected into the pronucleus of FVB/N embryos at a concentration of 2 ng/ml. Injected embryos were transferred into pseudopregnant females. Potential transgenic mice were screened by isolating genomic DNA from tail biopsies and testing for the presence of the MMTV-Aurora-A transgene using the PCR.
RT-PCR
Total RNA from mammary gland tissues was extracted using RNA Stat-60t (Tel-Test Inc., Friendswood, TX, USA). RT reactions were carried out using a first-strand cDNA synthesis kit (Roche Applied Science, Indianapolis, IN, USA). The cDNA samples were stored at À201C. Of total RNA, 1 mg from each sample was used as a template for each reaction, and 1 mg of cDNA from each sample was used for PCR. The optimal number of cycles for amplification was chosen according to the cycle number that yielded the strongest band while staying within the liner range. The primers used in this study were as follows: Hu-Aurora-A-1: 5 0 GTT TGA TGA GCA GAG ACC TGC 3 0 ; Hu-Aurora-A-2: 5 0 TTA AGC TCT CCA GCT GAT CC 3 0 and GAPDH-1: 5 0 ACA GCC GCA TCT TCT TGT GC 3 0 ; GAPDH-2: 5 0 TTT GAT GTT AGT GGG GTC TCG C 3 0 .
Histology and immunohistochemical analysis
Whole-mount preparation of mammary glands was performed as described (Deng and Xu, 2004) . Tissues were fixed in 10% neutralized buffered formalin and embedded in paraffin by standard procedures. Sections of 5 mm were stained with hematoxylin and eosin (H&E) or processed for immunohistochemistry analysis following antigen retrieval. Antibodies used are Pho-AKT (Ser473), Pho-GSK-3b (Ser21 and Ser9), and Pho-mTOR (Ser2448) (Cell Signaling, Beverly, MA, USA), Cyclin D1 (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Kip1/p27 (BD Transduction Laboratories, San Jose, CA, USA), and Anti-Phospho-Histone H3 (Upstate, Lake Placid, NY, USA).
BrdU labeling and TUNEL assays
At 2 h before killing, mice were injected with 20 ml/g of body weight of BrdU. To evaluate cell proliferation rates, BrdU incorporation was measured using a cell proliferation kit (Amersham, Piscataway, NJ, USA) following the manufacturer's instructions. The number of BrdU-positive cells in wildtype and MMTV-Aurora-A mammary glands were counted in 10 fields per slide under a Â 20 objective lens. TUNEL assays were performed on sections of mammary glands using the ApoTag Kit (Intergen Co., Purchase, NY, USA) as recommended by the manufacturer.
Western blot analysis
Western blot analysis was performed according to standard procedures. Mammary glands, tumor samples, or cells were lysed in ice-cold radioimmunoprecipitation assay buffer including protease inhibitors and phosphatase inhibitors.
Lysates were centrifuged at 13 200 r.p.m. for 20 min on a desk-top centrifuge, 50 mg of protein was separated on 8-16% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gradient gel (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membranes. After incubating with primary antibodies to Phospho-AKT, total AKT, or Aurora-A (all obtained from Cell Signaling, Beverly, MA, USA), peroxidaselabeled goad anti-rabbit immunoglobulin (Ig)G (H þ L) or goat anti-mouse IgG (H þ L) antibody (Kirkegarrd & Perry Laboratories, Gaithersburg, MD, USA) were used as secondary antibody. Western blots were developed with ECL Western blotting detection reagents (Amersham, Piscataway, NJ, USA) followed by autoradiography.
Cell culture, chromosome spread and treatment Primary culture of mammary epithelial cells was performed as described (Deng and Xu, 2004) . Briefly, mammary glands were rinsed in phosphate-buffered saline (PBS) and minced in MEBM/MEGM media (Clonetics, Palo Alto, CA, USA) containing 10 mg/ml of bacterial collagenase type III (Invitrogen, Carlsbad, CA, USA). After overnight digestion, released cells and finely minced tissues were pelleted, washed in PBS and cultured in MEBM/MEGM medium. After epithelial cells reached about 80% full, they were used for centrosome detection and chromosome preparation.
